Holding(s) in Company

Allergy Therapeutics PLC
21 March 2005


Schedule 10

NOTIFICATION OF MAJOR INTERSTS IN SHARES

1.   Name of Company

Allergy Therapeutics plc

2.   Name of shareholder having a major interest

Fidelity International Limited (FIL) and its direct and indirect subsidiaries

3.   Please state whether notification indicates that it is in
respect of holding of the shareholder names in 2 above or in respect of a
non-beneficial interest or in the case of children under the age of 18

Non-beneficial interest

4.  Name of the registered holder(s) and, if more than one
holder, the number of share held by each of them

Nominee/registered name Share held Management Company
JP Morgan, Bournemouth 757,100 Fidelity Inv Services Ltd
Bank of New York, Brussels 399,600 Fidelity Pension Mgmnt(FPM)
Bankers Trust London 103,400 FPM
CITIBANK London 128,400 FPM
Clydesdale Bank plc 42,300 FPM
JP Morgan, Bournemouth 220,900 FPM
Mellon Bank 232,100 FPM
Midland Securities Services 74,300 FPM
Northern Trust London 427,200 FPM
State STR BK and TR Co London 161,700 FPM

5.  Number of shares/amount of stock acquired

2,547,000

6.  Percentage of issued class

4.05%

7. Number of shares/amount of stock disposed

-

8. Percentage of issued class

-

9. Class of security

Ordinary shares

10. Date of transaction

Not notified

11. Date company informed

18th March 2005

12. Total holding following this notification

2,547,000

13. Total percentage holding of issued class following this
notification

4.05%

14. Any additional items

Notifiable interest also comprises the intrest of Mr.Edward C. Johnson 3d A
principal Shareholder of Fidelity International Limited

15. Name of contact and telephone number for queries

Ian Postlethwaite - 01903 844721

16.  Name and signature of authorised company official responsible
for make this notification

Ian Postlethwaite

Date of notification

21st March 2005

The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept liability for error or omission. The
FSA is not liable for any damages (including, without limitation, damages for
loss of business or loss of profits) arising in contract, tort or otherwise from
the use of or inability to use this document, or any material contained in it,
or from any action or decision taken as a result of using this document or any
such material.






                      This information is provided by RNS
            The company news service from the London Stock Exchange